biostudies-literatureKeravec MAssociations Vaincre la Mucoviscidose et Grégory Lemarchale000374https://www.ebi.ac.uk/biostudies/studies/S-EPMC6424284biostudies-literatureUnknown6(1)<h4>Introduction</h4><i>Pseudomonas aeruginosa</i> pulmonary infections are the primary cause of morbi-mortality in patients with cystic fibrosis (CF). In this cohort study, the objective was to identify candidate biomarkers of <i>P. aeruginosa</i> infection within the airway microbiota.<h4>Methods</h4>A 3-year prospective multicentre study (PYOMUCO study) was conducted in Western France and included patients initially <i>P. aeruginosa</i> free for at least 1 year. A 16S-targeted metagenomics approach was applied on iterative sputum samples of a first set of patients (n=33). The composition of airway microbiota was compared according to their <i>P. aeruginosa</i> status at the end of the follow-up (colonised vs non-colonised), and biomarkers associated with <i>P. aeruginosa</i> were screened. In a second step, the distribution of a candidate biomarker according to the two groups of patients was verified by qPCR on a second set of patients (n=52) coming from the same cohort and its load quantified throughout the follow-up.<h4>Results</h4><i>Porphyromonas</i> (mainly <i>P. catoniae</i>) was found to be an enriched phylotype in patients uninfected by <i>P. aeruginosa</i> (p<0.001). This result was confirmed by quantitative PCR. Conversely, in patients who became <i>P. aeruginosa-</i>positive, <i>P. catoniae</i> significantly decreased before <i>P. aeruginosa</i> acquisition (p=0.014).<h4>Discussion</h4>Further studies on replication cohorts are needed to validate this potential predictive biomarker, which may be relevant for the follow-up in the early years of patients with CF. The identification of infection candidate biomarkers may offer new strategies for CF precision medicine.BMJ open respiratory research<i>Porphyromonas</i>, a potential predictive biomarker of <i>Pseudomonas aeruginosa</i> pulmonary infection in cystic fibrosis.PMC6424284RC20170501971Barbier GVallet SKeravec MGuilloux CAGouriou SMondot SLepage PLe Berre RFerec CMounier JFangous MSHery-Arnaud GRault Gfalse<i>Porphyromonas</i>, a potential predictive biomarker of <i>Pseudomonas aeruginosa</i> pulmonary infection in cystic fibrosis.<h4>Introduction</h4><i>Pseudomonas aeruginosa</i> pulmonary infections are the primary cause of morbi-mortality in patients with cystic fibrosis (CF). In this cohort study, the objective was to identify candidate biomarkers of <i>P. aeruginosa</i> infection within the airway microbiota.<h4>Methods</h4>A 3-year prospective multicentre study (PYOMUCO study) was conducted in Western France and included patients initially <i>P. aeruginosa</i> free for at least 1 year. A 16S-targeted metagenomics approach was applied on iterative sputum samples of a first set of patients (n=33). The composition of airway microbiota was compared according to their <i>P. aeruginosa</i> status at the end of the follow-up (colonised vs non-colonised), and biomarkers associated with <i>P. aeruginosa</i> were screened. In a second step, the distribution of a candidate biomarker according to the two groups of patients was verified by qPCR on a second set of patients (n=52) coming from the same cohort and its load quantified throughout the follow-up.<h4>Results</h4><i>Porphyromonas</i> (mainly <i>P. catoniae</i>) was found to be an enriched phylotype in patients uninfected by <i>P. aeruginosa</i> (p<0.001). This result was confirmed by quantitative PCR. Conversely, in patients who became <i>P. aeruginosa-</i>positive, <i>P. catoniae</i> significantly decreased before <i>P. aeruginosa</i> acquisition (p=0.014).<h4>Discussion</h4>Further studies on replication cohorts are needed to validate this potential predictive biomarker, which may be relevant for the follow-up in the early years of patients with CF. The identification of infection candidate biomarkers may offer new strategies for CF precision medicine.2019-01-01T00:00:00Z20192026-06-16T07:02:12.161Z2019-06-05T15:43:03ZS-EPMC64242843095680210.1136/bmjresp-2018-000374